Cinfa MD discusses biosimilar products approaching the market

During the recent BIO-Europe partnering conference in Berlin, Mike Ward, global director of content for Informa Pharma Insights, caught up with Ruediger Jankowsky, managing director of Cinfa Biotech, to discuss the company's pipeline of biosimilar products for oncology and inflammatory diseases. Cinfa Biotech has one product under regulatory review in Europe, a biosimilar version of Amgen Inc.'s Neulasta (pegfilgrastim), which is used to treat chemotherapy-induced neutropenia. The Spanish firm is now seeking partners to commercialize this biosimilar drug once approved by regulators in Europe and other regions. Cinfa's MD says the company will also submit the drug to the US FDA soon.